[go: up one dir, main page]

SV2018005800A - Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4 - Google Patents

Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4

Info

Publication number
SV2018005800A
SV2018005800A SV2018005800A SV2018005800A SV2018005800A SV 2018005800 A SV2018005800 A SV 2018005800A SV 2018005800 A SV2018005800 A SV 2018005800A SV 2018005800 A SV2018005800 A SV 2018005800A SV 2018005800 A SV2018005800 A SV 2018005800A
Authority
SV
El Salvador
Prior art keywords
amina
acetilcoline
compounds
pirimidin
positive
Prior art date
Application number
SV2018005800A
Other languages
English (en)
Inventor
Craig W Lindsley
P Jeffrey Conn
Darren W Engers
Sean Bollinger
James C Tarr
Paul Spearing
Julie L Engers
Madeline Long
Thomas M Bridges
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60675830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2018005800(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of SV2018005800A publication Critical patent/SV2018005800A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Control Of El Displays (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Abstract

EN ESTE DOCUMENTO SE DIVULGAN COMPUESTOS TRICÍCLICOS, INCLUYENDO LOS COMPUESTOS PIRIMIDO [4', 5' : 4, 5] TIENO [2, 3-C] PIRIDAZIN-8-AMINA, PIRIDO [3' , 2' : 4, 5] TIENO [3, 2-D] PIRIMIDIN-4-AMINA, PIRAZINO [2', 3': 4, 5] TIENO [3, 2-D] PIRIMIDIN-4-AMINA, PIRIDO [3', 2' : 4, 5] FURO [3, 2-D] PIRIMIDIN-4-AMINA Y PIRIMIDO [4', 5' : 4, 5] FURO [2, 3-C] PIRIDAZIN-8-AMINA, QUE PUEDEN SER ÚTILES COMO MODULADORES ALOSTÉRICOS POSITIVOS DEL RECEPTOR MUSCARÍNICO DE ACETILCOLINA M4 (MACHR M4). EN ESTE DOCUMENTO TAMBIÉN SE DIVULGAN MÉTODOS DE PREPARACIÓN DE LOS COMPUESTOS, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS Y MÉTODOS DE TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS Y PSIQUIÁTRICOS ASOCIADOS CON EL MAL FUNCIONAMIENTO DEL RECEPTOR MUSCARÍNICO DE ACETILCOLINA USANDO LOS COMPUESTOS Y COMPOSICIONES.
SV2018005800A 2016-06-22 2018-12-12 Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4 SV2018005800A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353447P 2016-06-22 2016-06-22
US201662418638P 2016-11-07 2016-11-07
US201762471281P 2017-03-14 2017-03-14

Publications (1)

Publication Number Publication Date
SV2018005800A true SV2018005800A (es) 2019-02-13

Family

ID=60675830

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005800A SV2018005800A (es) 2016-06-22 2018-12-12 Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4

Country Status (30)

Country Link
US (5) US10239887B2 (es)
EP (2) EP3474846B1 (es)
JP (1) JP7038414B2 (es)
KR (1) KR102474326B1 (es)
CN (2) CN116178391A (es)
AU (1) AU2017281228B2 (es)
BR (1) BR112018003417B1 (es)
CL (1) CL2018003669A1 (es)
CO (1) CO2018013600A2 (es)
CR (1) CR20180598A (es)
DK (1) DK3474846T3 (es)
DO (1) DOP2018000263A (es)
EC (1) ECSP18094769A (es)
ES (1) ES2936827T3 (es)
FI (1) FI3474846T3 (es)
GE (2) GEP20207167B (es)
IL (1) IL263500B (es)
JO (1) JOP20180114B1 (es)
MA (1) MA45463A (es)
MX (1) MX385384B (es)
NI (1) NI201800141A (es)
PE (1) PE20190446A1 (es)
PH (1) PH12018502638B1 (es)
RU (1) RU2750935C2 (es)
SG (1) SG11201810794VA (es)
SV (1) SV2018005800A (es)
TN (1) TN2018000416A1 (es)
UA (1) UA125874C2 (es)
WO (1) WO2017223290A1 (es)
ZA (1) ZA201808219B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112719A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
ES2936827T3 (es) * 2016-06-22 2023-03-22 Univ Vanderbilt Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4
WO2018085813A1 (en) * 2016-11-07 2018-05-11 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
MA47126A (fr) 2016-11-07 2019-10-30 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
EP3534901B1 (en) 2016-11-07 2022-06-22 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
WO2019113174A1 (en) 2017-12-05 2019-06-13 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN110950774B (zh) * 2019-11-04 2021-04-13 北京大学 蛋白质定量标记试剂及其制备方法与应用
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
EP4100410A1 (en) * 2020-02-05 2022-12-14 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
CN116669737A (zh) * 2020-12-22 2023-08-29 范德堡大学 毒蕈碱型乙酰胆碱受体m4的拮抗剂
WO2022226078A1 (en) * 2021-04-20 2022-10-27 The Regents Of The University Of California Therapy for alcohol-related liver disease
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025129082A1 (en) * 2023-12-14 2025-06-19 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
AU2001231154A1 (en) * 2000-01-24 2001-07-31 Adherex Technologies Inc. Peptidomimetic modulators of cell adhesion
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2002009760A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US7291733B2 (en) * 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
AU2004282179B2 (en) * 2003-10-14 2011-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
AR049300A1 (es) 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
EP1773840B1 (de) 2004-07-23 2010-01-20 The Medicines Company (Leipzig) GmbH Substituierte pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
EP1619196A1 (de) 2004-07-23 2006-01-25 Curacyte Discovery GmbH Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur Verwendung als Inhibitoren der PDA-4 und/oder TNF-alpha Freisetzung
DK1807434T3 (da) 2004-10-25 2010-11-22 Lilly Co Eli Thienopyridiner som allosteriske potentiatorer af M4- muscarinreceptoren
ES2259891B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
ES2259892B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
AR059901A1 (es) 2006-03-20 2008-05-07 Bayer Pharmaceuticals Corp Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
US20080021063A1 (en) * 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
ES2656496T3 (es) * 2006-12-29 2018-02-27 Rigel Pharmaceuticals, Inc. Triazoles sustituidos útiles como inhibidores de AXL
AU2008240764C1 (en) * 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
MX2012002059A (es) 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
US20110178107A1 (en) 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
RU2451686C1 (ru) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ
WO2012131297A1 (en) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
WO2013040534A1 (en) 2011-09-16 2013-03-21 Vanderbilt University Substituted 1h-pyrazolo[3',4',4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulatiors of the muscarinic acetycholine receptor m4
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
KR102097343B1 (ko) 2011-12-21 2020-04-07 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 RAL GTPases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
US8697888B2 (en) * 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
EP3321257A1 (en) 2012-02-23 2018-05-16 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
US9056875B2 (en) * 2012-08-31 2015-06-16 Vanderbilt University Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
EP3036233A1 (en) 2013-08-23 2016-06-29 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US9981920B2 (en) * 2014-06-26 2018-05-29 Rodin Therapeutics, Inc. Inhibitors of histone deacetylase
ES2936827T3 (es) 2016-06-22 2023-03-22 Univ Vanderbilt Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4
WO2018085813A1 (en) 2016-11-07 2018-05-11 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3534901B1 (en) 2016-11-07 2022-06-22 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
MA47126A (fr) 2016-11-07 2019-10-30 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
WO2019113174A1 (en) * 2017-12-05 2019-06-13 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Also Published As

Publication number Publication date
GEAP202014954A (en) 2020-06-25
US11142532B2 (en) 2021-10-12
BR112018003417B1 (pt) 2023-10-24
RU2018142987A (ru) 2020-07-22
UA125874C2 (uk) 2022-06-29
ES2936827T3 (es) 2023-03-22
JOP20180114A1 (ar) 2019-01-30
NI201800141A (es) 2020-07-22
RU2018142987A3 (es) 2020-07-24
US10239887B2 (en) 2019-03-26
PH12018502638A1 (en) 2019-10-21
CN109310668B (zh) 2023-01-24
MX2018015878A (es) 2019-05-27
EP3474846B1 (en) 2022-11-30
CR20180598A (es) 2019-11-20
US20230014109A1 (en) 2023-01-19
RU2750935C2 (ru) 2021-07-06
BR112018003417A2 (es) 2018-10-02
KR102474326B1 (ko) 2022-12-05
CA3026578A1 (en) 2017-12-28
JP7038414B2 (ja) 2022-03-18
NZ748982A (en) 2024-11-29
CN116178391A (zh) 2023-05-30
IL263500B (en) 2021-09-30
JP2019523233A (ja) 2019-08-22
PH12018502638B1 (en) 2023-03-24
US20230348490A1 (en) 2023-11-02
CN109310668A (zh) 2019-02-05
MA45463A (fr) 2019-05-01
JOP20180114B1 (ar) 2022-09-15
ZA201808219B (en) 2020-05-27
CO2018013600A2 (es) 2018-12-28
US20190161498A1 (en) 2019-05-30
KR20190018645A (ko) 2019-02-25
AU2017281228A1 (en) 2018-12-20
MX385384B (es) 2025-03-18
FI3474846T3 (fi) 2023-02-16
PE20190446A1 (es) 2019-03-29
CL2018003669A1 (es) 2019-02-01
EP3474846A1 (en) 2019-05-01
IL263500A (en) 2019-01-31
EP3474846A4 (en) 2019-12-04
TN2018000416A1 (en) 2020-06-15
AU2017281228B2 (en) 2021-02-18
WO2017223290A1 (en) 2017-12-28
DOP2018000263A (es) 2019-03-31
ECSP18094769A (es) 2019-01-31
DK3474846T3 (da) 2023-02-06
GEP20207167B (en) 2020-10-12
SG11201810794VA (en) 2019-01-30
EP4186910A1 (en) 2023-05-31
US20250026764A1 (en) 2025-01-23
US20170369505A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
SV2018005800A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
CO6541572A2 (es) Octahidropirrolo[3.4-c]pirrolos distituidos como moduladores del receptor de orexina
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
MX2021006804A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
MX2019007379A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
BR112018013882A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
NZ737399A (en) Ccr2 modulators
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
CL2016002348A1 (es) Agonistas del receptor muscarínico
CL2015000898A1 (es) Compuestos derivados de pirrolo [3,2-d] pirimidinicos, moduladores de receptores toll (tlr); composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios o inflamatorios.
MX2015013711A (es) Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selecticos de receptor de nk-3, composicion farmaceutica y metodos para su uso en trastornos mediados por el receptor de nk-3.
WO2019123294A3 (en) Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus
ECSP088279A (es) Ciclopropil aminas como moduladores del receptor de histamina h3
BR112018013763A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilclona m4
CR9791A (es) Compuestos de pirimidina como moduladores de receptor de serotonina
BR112018016629A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
BR112018013879A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
CL2017000192A1 (es) Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostéricos negativos de receptores mglu2r2
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CL2017000249A1 (es) Compuestos de 6,7-dihidropirazolo [1,5-a] pirazin-4(5h)-ona y su uso como moduladores alostéricos negativos de receptores mglu2r2
CA3156666A1 (en) Muscarinic acetylcholine m1 receptor antagonists
BR112017025601A2 (pt) imidazopirazinas tricíclicas fundidas como moduladoras da atividade de tnf
WO2019113174A8 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4